E
13.66
3.29 (31.73%)
| Previous Close | 10.37 |
| Open | 15.06 |
| Volume | 569,553 |
| Avg. Volume (3M) | 769,706 |
| Market Cap | 41,513,148 |
| Price / Sales | 40.97 |
| Price / Book | 22.09 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2024 |
| Operating Margin (TTM) | -1,193.20% |
| Diluted EPS (TTM) | -2.02 |
| Total Debt/Equity (MRQ) | 453.50% |
| Current Ratio (MRQ) | 0.610 |
| Operating Cash Flow (TTM) | -3.84 M |
| Levered Free Cash Flow (TTM) | -2.03 M |
| Return on Assets (TTM) | -26.41% |
| Return on Equity (TTM) | -144.41% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Exicure, Inc. | Mixed | Mixed |
AIStockmoo Score
-1.7
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.0 |
| Average | -1.67 |
|
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 46.78% |
| % Held by Institutions | 4.29% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Northwestern University | 30 Sep 2024 | 10,430 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 Jan 2025 | Announcement | CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. |
| 26 Dec 2024 | Announcement | Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech |
| 20 Dec 2024 | Announcement | CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes |
| 14 Nov 2024 | Announcement | Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |